Alexion CEO Ludwig Hantson (file photo)
May 5, 2020 07:21 AM EDTUpdated 09:01 AM
Deals

Alex­ion bags a dis­count biotech buy­out for $1.4B, branch­ing out in new di­rec­tions from its Soliris fran­chise

John Carroll

Editor & Founder

Alex­ion is tak­ing a trip down to the dis­count base­ment for its next M&A deal. And this time the ex­ec­u­tive team wants to branch out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times